Modulation of DYRK1B expression
US10577607B2 · kind B2 · utility
0Cited by
186References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2017 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | Mar 16, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of DYRKIB in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual in need.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.